Vasileios Oikonomou
XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease.
Woelfel S, Dütschler J, Junker D, König M, Graf N, Krieger-Grübel C, Truniger S, Oikonomou V, Leinenkugel G, Koller S, Metzger-Peter K, Wyss J, Krupka N, Frei N, STAR SIGN Study Investigators, Albrich W, Friedrich M, Niess J, Schneiderhan-Marra N, Dulovic A, Misselwitz B, Korte W, Bürgi J, Brand S. XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease. Aliment Pharmacol Ther 2024
29.10.2024XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease.
29.10.2024Aliment Pharmacol Ther 2024
Woelfel Simon, Dütschler Joel, Junker Daniel, König Marius, Graf Nicole, Krieger-Grübel Claudia, Truniger Samuel, Oikonomou Vasileios, Leinenkugel Georg, Koller Seraina, Metzger-Peter Katline, Wyss Jacqueline, Krupka Niklas, Frei Nicola Fabian, STAR SIGN Study Investigators, Albrich Werner, Friedrich Matthias, Niess Jan-Hendrik, Schneiderhan-Marra Nicole, Dulovic Alex, Misselwitz Benjamin, Korte Wolfgang C, Bürgi Justus J, Brand Stephan
STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
Woelfel S, Dütschler J, König M, Dulovic A, Graf N, Junker D, Oikonomou V, Krieger-Grübel C, Truniger S, Franke A, Eckhold A, Forsch K, Koller S, Wyss J, Krupka N, Oberholzer M, Frei N, Geissler N, Schaub P, STAR SIGN Study Investigators, Albrich W, Friedrich M, Schneiderhan-Marra N, Misselwitz B, Korte W, Bürgi J, Brand S. STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2023; 58:678-691.
12.08.2023STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
12.08.2023Aliment Pharmacol Ther 2023; 58:678-691
Woelfel Simon, Dütschler Joel, König Marius, Dulovic Alex, Graf Nicole, Junker Daniel, Oikonomou Vasileios, Krieger-Grübel Claudia, Truniger Samuel, Franke Annett, Eckhold Annika, Forsch Kristina, Koller Seraina, Wyss Jacqueline, Krupka Niklas, Oberholzer Melanie, Frei Nicola Fabian, Geissler Nora, Schaub Peter, STAR SIGN Study Investigators, Albrich Werner, Friedrich Matthias, Schneiderhan-Marra Nicole, Misselwitz Benjamin, Korte Wolfgang C, Bürgi Justus J, Brand Stephan
Human Dectin-1 deficiency impairs macrophage-mediated defense against phaeohyphomycosis.
Drummond R, Desai J, Hsu A, Oikonomou V, Vinh D, Acklin J, Abers M, Walkiewicz M, Anzick S, Swamydas M, Vautier S, Natarajan M, Oler A, Yamanaka D, Mayer-Barber K, Iwakura Y, Bianchi D, Driscoll B, Hauck K, Kline A, Viall N, Zerbe C, Ferré E, Schmitt M, DiMaggio T, Pittaluga S, Butman J, Zelazny A, Shea Y, Arias C, Ashbaugh C, Mahmood M, Temesgen Z, Theofiles A, Nigo M, Moudgal V, Bloch K, Kelly S, Whitworth M, Rao G, Whitener C, Mafi N, Gea-Banacloche J, Kenyon L, Miller W, Boggian K, Gilbert A, Sincock M, Freeman A, Bennett J, Hasbun R, Mikelis C, Kwon-Chung K, Belkaid Y, Brown G, Lim J, Kuhns D, Holland S, Lionakis M. Human Dectin-1 deficiency impairs macrophage-mediated defense against phaeohyphomycosis. J Clin Invest 2022; 132
15.11.2022Human Dectin-1 deficiency impairs macrophage-mediated defense against phaeohyphomycosis.
15.11.2022J Clin Invest 2022; 132
Drummond Rebecca A, Desai Jigar V, Hsu Amy P, Oikonomou Vasileios, Vinh Donald C, Acklin Joshua A, Abers Michael S, Walkiewicz Magdalena A, Anzick Sarah L, Swamydas Muthulekha, Vautier Simon, Natarajan Mukil, Oler Andrew J, Yamanaka Daisuke, Mayer-Barber Katrin D, Iwakura Yoichiro, Bianchi David, Driscoll Brian, Hauck Ken, Kline Ahnika, Viall Nicholas Sp, Zerbe Christa S, Ferré Elise Mn, Schmitt Monica M, DiMaggio Tom, Pittaluga Stefania, Butman John A, Zelazny Adrian M, Shea Yvonne R, Arias Cesar A, Ashbaugh Cameron, Mahmood Maryam, Temesgen Zelalem, Theofiles Alexander G, Nigo Masayuki, Moudgal Varsha, Bloch Karen C, Kelly Sean G, Whitworth M Suzanne, Rao Ganesh, Whitener Cindy J, Mafi Neema, Gea-Banacloche Juan, Kenyon Lawrence C, Miller William R, Boggian Katia, Gilbert Andrea, Sincock Matthew, Freeman Alexandra F, Bennett John E, Hasbun Rodrigo, Mikelis Constantinos M, Kwon-Chung Kyung J, Belkaid Yasmine, Brown Gordon D, Lim Jean K, Kuhns Douglas B, Holland Steven M, Lionakis Michail S
Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
Woelfel S, Dütschler J, König M, Graf N, Oikonomou V, Krieger-Grübel C, Truniger S, Franke A, Eckhold A, Forsch K, Wyss J, Krupka N, Albrich W, Frei N, Geissler N, Schaub P, STAR SIGN Study Investigators, Friedrich M, Misselwitz B, Korte W, Bürgi J, Brand S. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2. Aliment Pharmacol Ther 2022; 57:103-116.
28.10.2022Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
28.10.2022Aliment Pharmacol Ther 2022; 57:103-116
Woelfel Simon, Dütschler Joel, König Marius, Graf Nicole, Oikonomou Vasileios, Krieger-Grübel Claudia, Truniger Samuel, Franke Annett, Eckhold Annika, Forsch Kristina, Wyss Jacqueline, Krupka Niklas, Albrich Werner, Frei Nicola Fabian, Geissler Nora, Schaub Peter, STAR SIGN Study Investigators, Friedrich Matthias, Misselwitz Benjamin, Korte Wolfgang C, Bürgi Justus J, Brand Stephan